KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin (2016 - 2025)

TherapeuticsMD's EBIT Margin history spans 16 years, with the latest figure at 173.8% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 7605.0% year-over-year to 173.8%; the TTM value through Dec 2025 reached 131.7%, up 19294.0%, while the annual FY2025 figure was 145.27%, 20181.0% up from the prior year.
  • EBIT Margin reached 173.8% in Q4 2025 per TXMD's latest filing, down from 109.95% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 70.65% in Q4 2022 to a low of 4269.25% in Q2 2022.
  • Average EBIT Margin over 5 years is 941.6%, with a median of 214.47% recorded in 2025.
  • Peak YoY movement for EBIT Margin: crashed -411631bps in 2022, then soared 370358bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 189.48% in 2021, then surged by 137bps to 70.65% in 2022, then plummeted by -554bps to 320.92% in 2023, then skyrocketed by 70bps to 97.75% in 2024, then crashed by -78bps to 173.8% in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EBIT Margin are 173.8% (Q4 2025), 109.95% (Q3 2025), and 73.0% (Q2 2025).